MRK Jun 2024 130.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:40PM EDT. Market open.
Loading interactive chart…
- Business Wire
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RAHWAY, N.J., June 05, 2024--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Simply Wall St.
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
- Business Wire
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
© 2024 Yahoo. All rights reserved.